ON POINT
LIVE

Serial Number

99175610

Owner

Avidity Biosciences, Inc.

Attorney

Aaron D. Hendelman

Filing Date

May 8, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ON POINT Trademark

Serial Number: 99175610

ON POINT is a trademark filed by Avidity Biosciences, Inc. on May 8, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Avidity Biosciences, Inc. (41 trademarks)

10578 Science Drive, Suite 125
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

May 8, 2025

Registration Date

Not Registered

Goods & Services

Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology; providing medical and scientific research information in the fields of pharmaceuticals, therapeutics, medicines and vaccines; none of the foregoing related to pharmacy services or pharmaceutical compounding services

Providing information relating to the diagnostic, prophylactic and therapeutic properties in the field of pharmaceuticals, therapeutics, medicines, and vaccines; online medical information services, namely, providing a website related to the diagnostic, prophylactic and therapeutic properties of medicines and vaccines; none of the foregoing related to medical care centers, medical services, medical clinics, pharmacy services, pharmaceutical compounding services, administration of pharmaceutical preparations, or drop-in medical clinics

Custom manufacturing of oligonucleotide-conjugate based pharmaceutical therapies, oligonucleotide-antibody conjugate based pharmaceutical therapies, and oligonucleotide-antibody fragment conjugate based pharmaceutical therapies; custom manufacturing of pharmaceuticals; contract manufacturing in the field of pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; none of the foregoing related to pharmacy services or pharmaceutical compounding services

Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; none of the foregoing related to pharmacy services or pharmaceutical compounding services

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 21, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 21, 2026 GNSL
SUSPENSION LETTER WRITTEN
Apr 21, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 27, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 27, 2026 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 5, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 5, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 5, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 5, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 5, 2026 COAR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Dec 4, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Dec 4, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 17, 2025 GNRN
NON-FINAL ACTION E-MAILED
Oct 17, 2025 GNRT
NON-FINAL ACTION WRITTEN
Oct 17, 2025 CNRT
ASSIGNED TO EXAMINER
Oct 16, 2025 DOCK
ASSIGNED TO EXAMINER
Sep 24, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 17, 2025 NWOS
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 5, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 5, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 5, 2025 COAR
APPLICATION FILING RECEIPT MAILED
May 8, 2025 MAFR
NEW APPLICATION ENTERED
May 8, 2025 NWAP